免疫检查点抑制剂对晚期胃腺鳞癌患者的持久疗效

Journal of Cancer Research and Practice Pub Date : 2022-10-01 DOI:10.4103/2311-3006.362634

Cheng-Lun Lai, M. Chen

{"title":"免疫检查点抑制剂对晚期胃腺鳞癌患者的持久疗效","authors":"Cheng-Lun Lai, M. Chen","doi":"10.4103/2311-3006.362634","DOIUrl":null,"url":null,"abstract":"Gastric adenosquamous carcinoma (GASC) is an extremely rare malignancy of the stomach. It is generally diagnosed at an advanced stage and is associated with a poor prognosis. Notably, the standard treatments for GASC remain undetermined because of the condition's rarity. In this report, we present a patient diagnosed with advanced GASC with positive predictive biomarkers for immune checkpoint inhibitors (ICIs), who achieved a durable response through nivolumab monotherapy. We also review and discuss the management of GASC and possible roles of ICIs in gastric cancers.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"9 1","pages":"145 - 148"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinoma\",\"authors\":\"Cheng-Lun Lai, M. Chen\",\"doi\":\"10.4103/2311-3006.362634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gastric adenosquamous carcinoma (GASC) is an extremely rare malignancy of the stomach. It is generally diagnosed at an advanced stage and is associated with a poor prognosis. Notably, the standard treatments for GASC remain undetermined because of the condition's rarity. In this report, we present a patient diagnosed with advanced GASC with positive predictive biomarkers for immune checkpoint inhibitors (ICIs), who achieved a durable response through nivolumab monotherapy. We also review and discuss the management of GASC and possible roles of ICIs in gastric cancers.\",\"PeriodicalId\":31219,\"journal\":{\"name\":\"Journal of Cancer Research and Practice\",\"volume\":\"9 1\",\"pages\":\"145 - 148\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/2311-3006.362634\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2311-3006.362634","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

胃腺鳞状细胞癌是一种极为罕见的胃恶性肿瘤。它通常在晚期被诊断出来，预后不良。值得注意的是，由于GASC的罕见性，其标准治疗方法尚未确定。在本报告中，我们介绍了一名被诊断为晚期GASC的患者，该患者具有免疫检查点抑制剂（ICIs）的阳性预测生物标志物，通过nivolumab单药治疗获得了持久的反应。我们还回顾和讨论了GASC的管理以及ICIs在胃癌中的可能作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinoma

Gastric adenosquamous carcinoma (GASC) is an extremely rare malignancy of the stomach. It is generally diagnosed at an advanced stage and is associated with a poor prognosis. Notably, the standard treatments for GASC remain undetermined because of the condition's rarity. In this report, we present a patient diagnosed with advanced GASC with positive predictive biomarkers for immune checkpoint inhibitors (ICIs), who achieved a durable response through nivolumab monotherapy. We also review and discuss the management of GASC and possible roles of ICIs in gastric cancers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cancer Research and Practice

自引率

0.00%

发文量

审稿时长

24 weeks

期刊介绍： JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.